X4 expects its efforts will decrease annual spending by $30-35 million and believes it will have sufficient funds to support operations into the first half of 2026. Workforce reductions are expected ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.